The investigational antibody therapy obexelimab lowered disease activity and reduced the need for glucocorticoid rescue therapy among people with immunoglobulin G4-related disease (IgG4-RD), according to final published data from a global clinical trial. The Phase 3 study, called INDIGO (NCT05662241), is the largest ever conducted in IgG4-RD,…
Discussion
Note: This column describes the author’s own experiences with Rituxan (rituximab) and thoughts on other treatments. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Four and a half years ago, I would have taken any route that promised a chance…
Zenas Biopharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its experimental injection therapy, obexelimab, for immunoglobulin G4-related disease (IgG4-RD). “Our obexelimab [biologics license application] submission brings us one step closer to our goal of delivering this…
Get regular updates to your inbox.
